Article

The return of RET GateKeeper mutations? An In-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046

2022-02-02

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose:</bold> TPX-0046 is designed to overcome resistance to FDA approved RET inhibitors Selpercatinib and Pralsetinib. Early prediction of resistance mechanisms to investigational drugs may facilitate subsequent drug and trial designs. This study aims to predict potential mutations inducing resistance to TPX-0046.<bold>Materials and methods:</bold> We conducted an in-silico ana...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1ca03f1e-f930-5777-8466-33e90e4e7b8d
DOI: 10.21203/rs.3.rs-1277120/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The return of RET GateKeeper mutations? An In-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046DOI 10.21203/rs.3.rs-1277120/v1Read

The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.Semantic proximity Read

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.Semantic proximity Read

Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1G2032R and ALKG1202R.Semantic proximity Read

Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Semantic proximity Read

RETaliation-Tackling Rare Resistance Alterations to Osimertinib.Semantic proximity Read

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.Semantic proximity Read

Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.Semantic proximity Read

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.Semantic proximity Read

In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALKL1196M/G1202R mutation.Semantic proximity Read

Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant MutationsSemantic proximity Read

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.Semantic proximity Read

Systematic profiling of Taxol resistance and sensitivity to tubulin missence mutations at molecular and cellular levels.Semantic proximity Read